Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS)

Sabesp (SBS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Sabesp (SBS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Here is how Sabesp (SBS) and Telenor ASA (TELNY) have performed compared to their sector so far this year.

Sabesp (SBS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Sabesp's net revenue grew 7.4% YoY, driven by higher volumes and significant tariff adjustments, especially a 20% increase for industrial clients. Operational efficiency soared, with EBITDA margin jumping from 54.9% to 66.1%, thanks to cost cuts and workforce reduction. CapEx surged 178% to meet regulatory targets, yet leverage remains healthy at 1.9x net debt/EBITDA, supporting continued investment.

Premier Latino Audiovisual Entertainment Destination to Reach Millions of Spanish-Speaking Viewers MIAMI , June 9, 2025 /PRNewswire/ -- Spanish Broadcasting System, Inc. (SBS), the largest Hispanic-controlled media and entertainment company in the United States, today announced that LaMusica, its top-ranked audiovisual entertainment app, will begin livestreaming as LaMusica TV on The Roku Channel. This summer, millions of Roku's Hispanic customers in the U.S. and Mexico will gain access to LaMusica TV via The Roku Channel, the #2 app on the Roku platform in the U.S. by engagement.

SAN JUAN, Puerto Rico , June 5, 2025 /PRNewswire/ -- Spanish Broadcasting System, Inc. (SBS), the largest minority-owned Hispanic media company in the U.S., has entered into an Asset Purchase Agreement for the sale of WVEO(DT), WTCV(DT), and WVOZ-TV Puerto Rico to Word of God Fellowship, Inc., a Christian faith-based broadcast owner-operator known as Daystar Television Network. This strategic sale reinforces SBS's focus on its core audio and digital businesses, continuing SBS's industry-leading radio portfolio dominance (including the most-listened-to-and-streamed station in the nation, WSKQ-FM, in New York City), along with its digital platforms (among which is included the highest-rated Latino music streaming app, LaMusica) in further serving and empowering Hispanic audiences across the US and Puerto Rico footprints.

SABESP operates in a rapidly developing market that offers substantial long-term growth opportunities. Its expanding customer base and increasing water demand support steady revenue expansion. The ongoing privatization process is unlocking significant value by improving operational efficiency and attracting strategic investments. This transition enhances both governance and growth prospects. SABESP's disciplined capital expenditure strategy is building a strong and sustainable competitive moat. Focused investments in infrastructure improve service quality and create high barriers to entry.

Water utilities like AWK, SBS, MSEX and ARTNA are likely to benefit from stable demand for water and wastewater services. Capital-intensive utilities are set to gain from interest rate cuts.

Invest in stocks of MVST, SBS, CARG and ATR to tap their high-efficiency levels.

Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP (NYSE:SBS ) Q1 2025 Results Conference Call May 13, 2025 7:00 AM ET Company Participants Daniel Szlak - Chief Financial Officer and Investor Relations Officer Carlos Piani - Chief Executive Officer Conference Call Participants Guilherme Lima - Santander Joao Pimentel - Citibank Maria Carolina - Safra Bruno Amorim - Goldman Sachs Luiza Candiota - Itau Francisco Navarrete - Banco Antonio Junqueira - BTG Pactual Andre Sampaio - Banco Santander Operator Good morning, and welcome to SABESP First Quarter of 2025 Earnings Presentation. With us here today are Carlos Piani, CEO; Daniel Szlak, CFO; and Thiago Levy, Investor Relations.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Sabesp (SBS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Sabesp (SBS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Jaguar to host investor webcast today at 8:30 AM Eastern to review the initial results from the proof-of-concept study of crofelemer for MVID and SBS-IF presented April 26 at the Annual ELITE PED-GI Congress ; Click here to register There are no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management including total parenteral nutrition (TPN) - which carries the risk of morbidity, infections, metabolic complications, liver and kidney problems, and neurodevelopmental delay This proof-of-concept data in MVID supports crofelemer's potential inclusion in the European Medicines Agency's (EMA) PRIME program for expediated and assisted regulatory approval in the EU as well as FDA's Breakthrough Therapies program for expedited regulatory approval in the US SAN FRANCISCO, CA / ACCESS Newswire / April 30, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced initial proof-of-concept results showing that a novel liquid formulation of crofelemer reduced the required TPN and/or supplementary intravenous fluids, collectively referred to as parenteral support (PS) in patients with intestinal failure due to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) by up to 27% and 12.5% respectively. In addition, this data showed that crofelemer reduced stool volume output and/or frequency of watery stools, and increased urine output - an indicator of improved nutrient oral absorption.

The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for crofelemer for MVID; Click here to register There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management This data was presented at the Annual ELITE PED-GI Congress by Dr. Mohamad Miqdady, a recognized leader in pediatric gastroenterology and the primary investigator for this study SAN FRANCISCO, CA / ACCESS Newswire / April 29, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today issued a reminder that Jaguar is hosting an investor webcast on Wednesday, April 30, 2025 at 8:30 AM Eastern to review the initial results of the proof-of-concept investigator-initiated trial of a novel liquid formulation of crofelemer, Jaguar's plant-based anti-secretory prescription drug, in patients with the rare diseases microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF) that were presented by Dr. Mohamad Miqdady on April 26, 2025 at the 11th Annual ELITE PED-GI Congress in Abu Dhabi in the United Arab Emirates. Participation Instructions for Jaguar Investor Webcast When: Wednesday, April 30, 2025 at 8:30 AM Eastern Time Where: Online Registration link for conference: Click Here About Crofelemer Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as "dragon's blood," of the Croton lechleri tree in the Amazon Rainforest.

SABESP is just beginning to unlock the benefits of privatization, with a bold R$70 billion investment plan through 2030 aimed at full sanitation coverage. Despite macro headwinds in Brazil, SBS ADRs have outperformed, buoyed by privatization momentum and significant operational upside. The stock still trades at an attractive EV/RAB of 1.22x, not fully reflecting future execution or asset base growth.